UBS AM
FPRX

UBS AM’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

UBS AM’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-26,622
Closed -$103K – 2917
2019
Q3 		$103K Buy
26,622
+16,146
+154% +$88.6K ﹤0.01% 2660
2019
Q2 		$63.2K Sell
10,476
-4,480
-30% -$42.8K ﹤0.01% 2673
2019
Q1 		$200K Buy
+14,956
New +$171K ﹤0.01% 2461
2018
Q2 		– Sell
-96,858
Closed -$1.66M – 2817
2018
Q1 		$1.66M Hold
96,858
– – ﹤0.01% 1551
2017
Q4 		$2.12M Sell
96,858
-10,832
-10% -$348K ﹤0.01% 1415
2017
Q3 		$4.41M Buy
107,690
+5,600
+5% +$176K ﹤0.01% 1130
2017
Q2 		$3.07M Sell
102,090
-20,130
-16% -$628K ﹤0.01% 1205
2017
Q1 		$4.42M Sell
122,220
-34,081
-22% -$1.5M ﹤0.01% 1048
2016
Q4 		$7.83M Buy
156,301
+129,404
+481% +$6.8M 0.01% 915
2016
Q3 		$1.41M Buy
26,897
+3,176
+13% +$152K ﹤0.01% 1521
2016
Q2 		$981K Buy
23,721
+851
+4% +$37K ﹤0.01% 1656
2016
Q1 		$929K Sell
22,870
-5,432
-19% -$187K ﹤0.01% 1666
2015
Q4 		$1.17M Buy
+28,302
New +$949K ﹤0.01% 1670
2015
Q3 		– Sell
-9,600
Closed -$238K – 2710
2015
Q2 		$238K Buy
+9,600
New +$214K ﹤0.01% 2504

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM's FPRX Position: Q4 2019 in Review

UBS AM sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2019, closing a stake of 26,622 shares — an estimated $103K sold.

UBS AM first reported a position in FPRX in Q2 2015 and held it in 14 quarters. The position peaked at $7.83M in Q4 2016. 94 funds tracked by Wall St. Rank hold FPRX as of Q4 2019.

  • UBS AM reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • UBS AM sold 26,622 Five Prime Therapeutics, Inc. shares in Q4 2019, an estimated $103K.
  • UBS AM first reported a position in Five Prime Therapeutics, Inc. in Q2 2015 and held it in 14 quarters.
  • UBS AM's Five Prime Therapeutics, Inc. position peaked at $7.83M in Q4 2016.
  • 94 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2019.

Based on UBS AM's 13F filing for Q4 2019, filed 14 Feb 2020.